Navigation Links
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Date:6/1/2009

al industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (or increase remission rates or progress free survival) for treatment of relapsed or refractory aggressive NHL as determined by the FDA, the possibility that the NDA submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

    Medical Information Contact:
    T: 800.715.0944
    E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
2. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
3. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
7. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
8. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
9. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
10. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
11. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... the most attractive in the emerging European region, mainly ... and increasing government investment in healthcare, according to a ... set to grow at twice the pace of the ... reaching an approximate market value of $43-60 billion by ... Cross provides total healthcare solutions that address the evolving ...
(Date:3/25/2015)... March 25, 2015 Optimal Research, LLC has ... Excellence (ViE) Award "Best Clinical Site or Trial Network". ... Optimal has been selected as a nominee in this ... a "Highly Recommended" distinction in 2014. The ViE awards ... efforts, accomplishments, and positive contributions of companies and individuals ...
(Date:3/25/2015)... IL (PRWEB) March 25, 2015 ... Symmetry® Top-Loading Balances and Analytical Balances to get ... expanded line of weighing balances from the trusted ... Toploading Balances increase your efficiency by providing ... variety of samples. Weighing modes include parts counting, ...
(Date:3/25/2015)... March 25, 2015 An increase of ... in all forms of food nutrients, regulatory changes and ... substantial rise in demand for natural astaxanthin over the ... to ramp up their capacities to satisfy the rising ... and synthetic source astaxanthin (used in nutraceuticals, aqua feed, ...
Breaking Biology Technology:Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2
... 23 BioRelix, pioneers in the discovery and ... Dalton Medicinal Chemistry have jointly announced an ... and agreement to discover and develop new therapeutics.Dalton ... the design and synthesis of new classes of ...
... new study examining the aftereffects of a chlorine gas disaster ... insight into what to expect and how to prepare emergency ... potentially deadly gas. The study is now available in the ... Medicine . , "This is one of the largest ...
... 20 Isolagen(TM), Inc. (Amex: ILE ) ... notice from the Amex (the "Exchange") notifying the Company ... the Exchange,s Company Guide (the "Company Guide"). Specifically, the ... are so substantial in relation to its overall operations ...
Cached Biology Technology:BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches 2New study examines effects of Graniteville, S.C., chlorine gas disaster 2New study examines effects of Graniteville, S.C., chlorine gas disaster 3Isolagen, Inc. Receives Notification Letter from Amex 2Isolagen, Inc. Receives Notification Letter from Amex 3Isolagen, Inc. Receives Notification Letter from Amex 4
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... , March 12, 2015 ... standardized identity and access management (IAM) solution for ... schedule. With Beta System,s new IAM package, customers ... practices gleaned from multiple IAM implementations across different ... software as well as any necessary services and ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... found a surprising link between brain iron levels ... ranging from autism to major depression., Appearing in ... Sciences this week, the study by Randy ... of a powerful in silico approach for discovering ...
... Wegener Institute for Polar and Marine Research in ... expedition LOHAFEX". Independent scientific and legal reviews sought ... and the Federal Ministry for the Environment, Nature ... fertilisation experiment LOHAFEX is neither against environmental standards ...
... Drug Administration is reconsidering the use of stimulants to ... to support a University of Houston professor,s theory that ... order. Richard A. Bond, professor of ... (UHCOP), has been investigating whether beta-2 adrenoreceptor antagonist drugs ...
Cached Biology News:Researchers iron out new role for serotonin 2Polarstern expedition 'LOHAFEX' can be conducted 2Polarstern expedition 'LOHAFEX' can be conducted 3New asthma research opposes current drug treatment, says UH prof 2New asthma research opposes current drug treatment, says UH prof 3New asthma research opposes current drug treatment, says UH prof 4
7G10 anti-Fasciclin III...
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
Biology Products: